Limits...
Biologic-free remission of established rheumatoid arthritis after discontinuation of abatacept: a prospective, multicentre, observational study in Japan.

Takeuchi T, Matsubara T, Ohta S, Mukai M, Amano K, Tohma S, Tanaka Y, Yamanaka H, Miyasaka N - Rheumatology (Oxford) (2014)

Bottom Line: Clinical, functional and structural outcomes were compared between those who continued and those who discontinued abatacept.Those attaining DAS28-CRP < 2.3 or < 2.7 without abatacept at the endpoint had significantly lower HAQ-DI score and/or CRP at enrolment.Non-serious adverse events occurred in three patients who continued or resumed abatacept.

View Article: PubMed Central - PubMed

Affiliation: Division of Rheumatology, Department of Internal Medicine, School of Medicine, Keio University, Tokyo, Department of Rheumatology, Matsubara Mayflower Hospital, Kato, Department of Rheumatology, Taga General Hospital, Hitachi, Division of Rheumatology and Clinical Immunology, Department of Medicine, Sapporo City General Hospital, Sapporo, Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Kawagoe, Clinical Research Center for Allergy and Rheumatology, National Hospital Organization Sagamihara National Hospital, Sagamihara, First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health Hospital, Kitakyushu, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo and Tokyo Medical and Dental University, Tokyo, Japan. tsutake@z5.keio.jp.

Show MeSH

Related in: MedlinePlus

Total Sharp score
© Copyright Policy - creative-commons
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4372674&req=5

keu338-F4: Total Sharp score

Mentions: The TSS at weeks 0 and 52 was similar in the discontinuation and continuation groups, but the baseline TSS was higher for the continuation group (Fig. 4A). Mean ΔTSS (0.80 vs 0.32, P = 0.374) and ΔJE (−0.02 vs 0.32, P = 0.466) were similar for the two groups, while mean ΔJSN was significantly greater in the discontinuation group (0.82 vs 0, P = 0.035; Fig. 4B). After correction by linear extrapolation, the proportion of patients in radiographic remission (ΔTSS ≤ 0.5) was 64.3% in the discontinuation group compared with 70.6% in the continuation group (P = 0.752; Fig. 4C). No radiographic progression was seen in 42.9% and 47.1% of patients, while RRP was seen in 14.3% and 0% of patients in the discontinuation and continuation groups, respectively (Fig. 4C). The four patients who showed RRP after discontinuation had significantly higher CRP at enrolment in this study and lower RF in the previous phase III study compared with the 24 patients who did not show RRP in this group (P = 0.034 and P = 0.020, respectively).Fig. 4


Biologic-free remission of established rheumatoid arthritis after discontinuation of abatacept: a prospective, multicentre, observational study in Japan.

Takeuchi T, Matsubara T, Ohta S, Mukai M, Amano K, Tohma S, Tanaka Y, Yamanaka H, Miyasaka N - Rheumatology (Oxford) (2014)

Total Sharp score
© Copyright Policy - creative-commons
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4372674&req=5

keu338-F4: Total Sharp score
Mentions: The TSS at weeks 0 and 52 was similar in the discontinuation and continuation groups, but the baseline TSS was higher for the continuation group (Fig. 4A). Mean ΔTSS (0.80 vs 0.32, P = 0.374) and ΔJE (−0.02 vs 0.32, P = 0.466) were similar for the two groups, while mean ΔJSN was significantly greater in the discontinuation group (0.82 vs 0, P = 0.035; Fig. 4B). After correction by linear extrapolation, the proportion of patients in radiographic remission (ΔTSS ≤ 0.5) was 64.3% in the discontinuation group compared with 70.6% in the continuation group (P = 0.752; Fig. 4C). No radiographic progression was seen in 42.9% and 47.1% of patients, while RRP was seen in 14.3% and 0% of patients in the discontinuation and continuation groups, respectively (Fig. 4C). The four patients who showed RRP after discontinuation had significantly higher CRP at enrolment in this study and lower RF in the previous phase III study compared with the 24 patients who did not show RRP in this group (P = 0.034 and P = 0.020, respectively).Fig. 4

Bottom Line: Clinical, functional and structural outcomes were compared between those who continued and those who discontinued abatacept.Those attaining DAS28-CRP < 2.3 or < 2.7 without abatacept at the endpoint had significantly lower HAQ-DI score and/or CRP at enrolment.Non-serious adverse events occurred in three patients who continued or resumed abatacept.

View Article: PubMed Central - PubMed

Affiliation: Division of Rheumatology, Department of Internal Medicine, School of Medicine, Keio University, Tokyo, Department of Rheumatology, Matsubara Mayflower Hospital, Kato, Department of Rheumatology, Taga General Hospital, Hitachi, Division of Rheumatology and Clinical Immunology, Department of Medicine, Sapporo City General Hospital, Sapporo, Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Kawagoe, Clinical Research Center for Allergy and Rheumatology, National Hospital Organization Sagamihara National Hospital, Sagamihara, First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health Hospital, Kitakyushu, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo and Tokyo Medical and Dental University, Tokyo, Japan. tsutake@z5.keio.jp.

Show MeSH
Related in: MedlinePlus